特写特讯！《长空之王》翱翔银幕 新浪观影团邀您共赴五一观影盛宴

《长空之王》翱翔银幕 新浪观影团邀您共赴五一观影盛宴

北京 - 2023年4月18日，新浪观影团宣布将在五一假期期间举办电影《长空之王》的免费观影活动，邀请广大影迷共同感受中国空军翱翔蓝天的壮志豪情。活动将于4月29日（周六）在北京金逸影城朝阳大悦城店举行，共计20张电影票将赠送给幸运网友。

电影《长空之王》以新时代中国空军为背景，讲述了雷宇（王一博饰）等优秀飞行员经过严苛选拔，成为试飞员，在队长张挺（胡军饰）的带领下，参与到最新型战机的试飞，一次次与死神过招，为祖国蓝天奉献热血的故事。影片场面震撼，特效逼真，展现了中国空军的强大实力和无畏精神，在大银幕上必将燃起观众的热血和自豪感。

新浪观影团一直致力于为广大影迷提供优质的观影体验，此次免费观影活动旨在为观众带来一场精彩的视觉盛宴，同时也希望借此机会向中国空军致敬。

活动规则

1. 关注@新浪观影团
2. 带话题#新浪观影团# 转发活动微博
3. 点击下方【+参加活动】按钮，填写报名信息

活动奖品

一等奖：电影《长空之王》电影票 20张

获奖名单

将于4月28日（周五）在@新浪观影团 官微公布

观影须知

1. 中奖者需凭本人身份证和获奖短信于4月29日（周六）18:30-18:50到北京金逸影城朝阳大悦城店进行签到
2. 观影结束后，请所有中奖者于4月30日（周日）23:59前点击《长空之王》点评页为本片打分并发布不少于140字的原创观后感

新浪观影团诚挚邀请广大影迷积极参与本次活动，共同感受电影《长空之王》的震撼魅力，为中国空军点赞！

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.